Related Experiment Videos
Rh negative status and isoimmunization update: a case-based approach to care.
Kathryn Shisler Harrod1, Lisa Hanson, Leona VandeVusse
1Nurse-Midwifery Program, Marquette University College of Nursing, Milwaukee, WI 53201-1881, USA.
The Journal of Perinatal & Neonatal Nursing
|September 10, 2003
Summary
Rho (D) immune globulin (RIG) prevents hemolytic disease of the newborn in Rh-negative women. Despite its use, Rh isoimmunization remains a challenge, requiring ongoing vigilance in perinatal and neonatal care.
Area of Science:
- Perinatal Medicine
- Immunology
- Neonatology
Background:
- Hemolytic disease of the newborn (HDN) caused significant morbidity and mortality before the 1970s.
- Rho (D) immune globulin (RIG) revolutionized prevention of HDN in Rh-negative women.
- Antepartum RIG administration became standard in 1983, yet Rh isoimmunization persists.
Observation:
- Rh isoimmunization, leading to erythroblastosis fetalis and hydrops fetalis, continues to pose clinical challenges.
- Evidence regarding prenatal and postpartum RIG administration is reviewed, highlighting controversies.
- Current fetal and neonatal care strategies for HDN are discussed.
Findings:
- RIG has dramatically reduced HDN incidence but has not completely eradicated Rh sensitization.
- Clinical challenges persist in managing Rh-related fetal and neonatal complications.
- Optimal timing and protocols for RIG administration remain areas of active consideration.
Implications:
- Continued education and adherence to best practices are crucial for perinatal and neonatal nurses.
- Further research may be needed to address remaining gaps in Rh isoimmunization prevention and management.
- Improved understanding and application of RIG therapy can further reduce adverse outcomes in Rh-sensitized pregnancies.